BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27365424)

  • 1. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
    Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
    Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model.
    Jeon YW; Lim JY; Im KI; Kim N; Nam YS; Song YJ; Cho SG
    Stem Cells Dev; 2019 Jan; 28(2):129-140. PubMed ID: 30381994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human LAP
    Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
    Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
    Pillai AB; George TI; Dutt S; Strober S
    Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
    Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.
    Nishikii H; Kim BS; Yokoyama Y; Chen Y; Baker J; Pierini A; Alvarez M; Mavers M; Maas-Bauer K; Pan Y; Chiba S; Negrin RS
    Blood; 2016 Dec; 128(24):2846-2858. PubMed ID: 27760760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A; Noble A
    J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.
    Hasegawa H; Inoue A; Kohno M; Lei J; Miyazaki T; Yoshie O; Nose M; Yasukawa M
    Gene Ther; 2008 Feb; 15(3):171-82. PubMed ID: 17989707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of TNF-α on Regulatory T Cell Function in Graft-versus-Host Disease.
    Mancusi A; Piccinelli S; Velardi A; Pierini A
    Front Immunol; 2018; 9():356. PubMed ID: 29541073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation.
    Lim DG; Koo SK; Park YH; Kim Y; Kim HM; Park CS; Kim SC; Han DJ
    Transplantation; 2010 Apr; 89(8):928-36. PubMed ID: 20305583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bim regulates the survival and suppressive capability of CD8
    Agle K; Vincent BG; Piper C; Belle L; Zhou V; Shlomchik W; Serody JS; Drobyski WR
    Blood; 2018 Jul; 132(4):435-447. PubMed ID: 29769260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
    Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
    Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.